BioSpace News Archive

Drug Development

New Hope for Oral Flu Vaccine as Prime Season Descends

Scientists from Stanford University investigated the effectiveness of an oral tablet flu vaccine called VXA-A1.1 by Vaxart, which uses cellular correlates of protection.

November 19, 2021
·
2 min read
·
Vanessa Doctor, RN
BioCapital

Clinical Catch-Up: November 15-19

With the last full week before the Thanksgiving week in the U.S., companies had a fair amount of clinical trial news. Here’s a look.

November 19, 2021
·
8 min read
·
Mark Terry
Pharm Country

New Freedoms Could Catapult J&J Pipeline Following Split

A week after announcing its intention to spin off its consumer health division, J&J revealed ambitious plans for its pharmaceutical business.

November 19, 2021
·
4 min read
·
Heather McKenzie
Drug Development

BioNTech Bags Fast-Track Status for Melanoma Treatment

BioNTech is on the Fast Track. This morning, the company announced it received Fast Track Designation from the U.S. Food and Drug Administration for its cancer immunotherapy candidate.

November 19, 2021
·
2 min read
·
Alex Keown
Drug Development

New Mavacamten PDUFA Date Will Allow Further Risk Mitigation Review

The extension will give the FDA sufficient time to look into the drug for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

November 19, 2021
·
2 min read
·
Vanessa Doctor, RN
Policy

Professor Under Fire for Undisclosed Chinese Military Ties

A Chinese professor at the University of Copenhagen in Denmark is under scrutiny over undisclosed ties to the Chinese military.

November 19, 2021
·
2 min read
·
Alex Keown
FDA

BioMarin Scores a First Day After Filing Trade Secrets Lawsuit

BioMarin Pharmaceutical scored a first on Friday and provided an option for patients with a rare disease for which there is little recourse.

November 19, 2021
·
4 min read
·
Alex Keown
Drug Development

COVID-19 Update: Major Global Spikes and AstraZeneca’s Antiviral Continues to Excite

While COVID-19 appears to be battling back in cold-weather states in the U.S. and parts of Europe, researchers continue to study vaccine efficacy and new approaches to dosing. Here’s a look.

November 19, 2021
·
4 min read
·
Mark Terry
Drug Development

Safety Signals Force Merck and Enanta to Scrap HIV and HBV Programs

If the road to success is paved with failures, then the road to an effective, approved drug is paved with flops. Merck and Enanta are adding some painful pavers to their own roads this week.

November 19, 2021
·
3 min read
·
Kate Goodwin
Policy

New Study Points to Wuhan Market as COVID-19’s Likely Origin

The two dominant theories over the origins of COVID-19 are that the virus developed naturally, probably from bats in a wet market in Wuhan, China, and the “lab leak.”

November 19, 2021
·
4 min read
·
Mark Terry